Relative and absolute numbers of total CD3+, CD3+4+, CD3+8+, CD3+16+ and CD3+56+ cells in PB of patients presenting with AML and age-matched healthy volunteers
| . | Total CD3+ (± SD) . | CD3+4+ (± SD) . | CD3+8+ (± SD) . | CD3+16+ (± SD) . | CD3+56+ (± SD) . |
|---|---|---|---|---|---|
| Healthy, n = 17 | |||||
| Relative | 61% (10%) | 64.44% (11.6%) | 30.77% (10.35%) | 3.14% (1.83%) | 2.96% (2.27%) |
| Absolute, ×106/L | 830 (32) | 536.2 (22.4) | 263.4 (17.0) | 24.7 (2.2) | 27.6 (12.8) |
| AML, n = 36 | |||||
| Relative | 13.15%* (19.2%) | 51.64%* (13.31%) | 36.87% (12.77%) | 1.52%* (1.98%) | 9.33%* (6.95%) |
| Absolute, ×106/L | 1900* (154) | 1038.7* (103.2) | 722.2* (65.7) | 23.3 (7.1) | 178.7* (54.2) |
| . | Total CD3+ (± SD) . | CD3+4+ (± SD) . | CD3+8+ (± SD) . | CD3+16+ (± SD) . | CD3+56+ (± SD) . |
|---|---|---|---|---|---|
| Healthy, n = 17 | |||||
| Relative | 61% (10%) | 64.44% (11.6%) | 30.77% (10.35%) | 3.14% (1.83%) | 2.96% (2.27%) |
| Absolute, ×106/L | 830 (32) | 536.2 (22.4) | 263.4 (17.0) | 24.7 (2.2) | 27.6 (12.8) |
| AML, n = 36 | |||||
| Relative | 13.15%* (19.2%) | 51.64%* (13.31%) | 36.87% (12.77%) | 1.52%* (1.98%) | 9.33%* (6.95%) |
| Absolute, ×106/L | 1900* (154) | 1038.7* (103.2) | 722.2* (65.7) | 23.3 (7.1) | 178.7* (54.2) |
PB indicates peripheral blood; AML, acute myeloid leukemia; and SD, standard deviation.
P <. 05 in a 2-tailed unpaired t test. For total CD3, the relative number relates to CD3+ cells as a percentage of live mononuclear cells. For other subsets, the relative number relates to the cells as a percentage of total CD3+ cells.